HSE100013
25005
elafibranor
Iqirvo®
Indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
Rapid Review Completed
13/03/2025